Review anchor
Uracil nucleotide/cysteinyl leukotriene receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Uracil nucleotide/cysteinyl leukotriene receptor
CHEMBL1075162
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Uracil nucleotide/cysteinyl leukotriene receptor as ChEMBL target CHEMBL1075162, mapped to UniProt Q13304. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL1075162
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13304
Uracil nucleotide/cysteinyl leukotriene receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Uracil nucleotide/cysteinyl leukotriene receptor matters
Uracil nucleotide/cysteinyl leukotriene receptor is reviewed as Uracil nucleotide/cysteinyl leukotriene receptor (UniProt Q13304); the current evidence base includes 4 approved drugs, 134 compounds, and 58 assays, with lead potency reaching pChEMBL 10.4.
Protein context
Uracil nucleotide/cysteinyl leukotriene receptor
Uracil nucleotide/cysteinyl leukotriene receptor Sequence length is 367 aa.
Review this target as Uracil nucleotide/cysteinyl leukotriene receptor, mapped to UniProt Q13304. Sequence length is 367 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q13304
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 4 approved drugs, 134 compounds, and 58 assays for this target. The dominant activity type is EC50. CHEMBL1097652 is the current potency anchor at pChEMBL 10.4.
Use CHEMBL1097652 as the tractability anchor when discussing potency (pChEMBL 10.4).
Activity source · ChEMBL 36 via Core Engine
4 approved
pChEMBL 10.4
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Uracil nucleotide/cysteinyl leukotriene receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q13304, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
134
Total Compounds
58
Total Assays
4
Approved Drugs
IC50: 48.0, KI: 8.0, EC50: 97.0, KD: 3.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1097652
|
10.4 | EC50 | — |
|
|
No preferred name
CHEMBL1097279
|
9.2 | IC50 | Approved |
|
|
No preferred name
CHEMBL1096742
|
8.8 | EC50 | — |
|
|
No preferred name
CHEMBL1098419
|
8.8 | EC50 | — |
|
|
No preferred name
CHEMBL31344
|
8.2 | EC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
CANGRELOR TETRASODIUM
CHEMBL1097279
|
2015 |
Source Header